Biosynex SA announced on June 13 that it entered an agreement to acquire ProciseDx for an undisclosed price. According to data captured in the LevinPro HC database, this transaction represents the 68th Laboratories, MRI and Dialysis acquisition of 2023, and the 33rd in the diagnostic subsector.
ProciseDx is an in vitro diagnostics company with a proprietary instrument platform and portfolio of point-of-care diagnostic tests. It is based in San Diego, California.
Biosynex is a French market leader specializing in the design and distribution of rapid tests. Biosynex designs, manufactures and distributes Rapid Diagnostic Tests, as well as diagnostic equipment for healthcare professionals and the general public.
With the support of the Biosynex Group, ProciseDx expects to commercialize the first FDA approved infliximab and adalimumab drug monitoring tests later this year.
This marks Biosynex’s second acquisition of the year, following its purchase of Chembio Diagnostics, Inc., a point-of-care diagnostics company focused on infectious diseases, in January. This also follows Biosynex’s acquisition of AVALUN SAS, an in vitro diagnostics company specializing in point-of-care testing, in April 2021.
